First in Indonesia Detection of COVID-19 by isothermal molecular test
COVID-19 testing is also an effective solution in preventing the spread of COVID-19 infection and has become one of the main efforts to ensure the safety of community when they return to work, school and other activities. With a commitment to provide the best quality service with international standards, BIMC Hospital Bali (as part of the Siloam Hospitals Group) provides the first Abbott ID NOW rapid molecular isothermal test in Indonesia.
The isothermal molecular test is a new and high-performance method of COVID-19 early detection. The sample for this type of test is taken through a nasopharyngeal swab. The isothermal molecular test method uses isothermal nucleic acid amplification, which results in a shorter examination process time; with results available within just 15 minutes. The sensitivity of the test results are 95.0% with a specificity of 97.9%.
The ID NOW isothermal molecular assay is certified by the Food and Drugs Administration (FDA) for Emergency Use Authorization (EUA) and is CLIA Waived certified for tests that can be used outside the laboratory or POCT (Point of Care Test).
The reading of test results is done by looking directly at the isothermal machine, showing a positive or negative result. In general, a positive test result indicates that you are most likely infected with COVID-19. However, a negative result does not rule out the possibility of COVID-19. Further tests will be needed to be carried out within 48 hours to confirm the results. Always review your results with the physician at BIMC Hospitals Bali who will help you determine next steps from their recommendation.
This molecular-based isothermal test for Covid-19 early screening is available at BIMC Hospital for IDR 1,299,000. For corporate deals, please contact Fransiska at +62 8111 077 003 (WhatsApp only)